North America’s medical devices industry saw a drop of 13.40% in deal activity during September 2021, when compared with the last 12-month average, led by Baxter International’s $12.4bn acquisition of Hill-Rom Holdings, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 84 medical devices industry deals worth $16.1bn were announced for the region in September 2021, against the 12-month average of 97 deals.
Of all the deal types, venture financing saw most activity in September 2021 with 59 transactions, representing a 70.2% share for the region.
In second place was M&A with 21 deals, followed by private equity deals with four transactions, respectively capturing a 25% and 4.8% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $15.02bn, while venture financing and private equity deals totalled $1.01bn and $45m, respectively.
North America medical devices industry deals in September 2021: Top deals
The top five medical devices deals accounted for 91.9% of the overall value during September 2021.
The combined value of the top five medical devices deals stood at $14.78bn, against the overall value of $16.1bn recorded for the month.
The top five medical devices industry deals of September 2021 tracked by GlobalData were:
1) Baxter International $12.4bn acquisition deal with Hill-Rom Holdings
2) The $1.45bn acquisition of BK Medical Systems by GE Healthcare
3) Boston Scientific $336m acquisition deal for 84% stake in DeVoro Medical
4) The $300m acquisition of Agena Bioscience by Mesa Laboratories
5) Cardio Partners $290m acquisition deal with Allied 100
